$PBIO SOUTH EASTON, Massachusetts, April 16, 2020
Post# of 23607
(Total Views: 139)
Posted On: 04/27/2020 10:45:51 AM
$PBIO SOUTH EASTON, Massachusetts, April 16, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT" with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS" resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS" . The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development.
https://www.wsj.com/articles/PR-CO-20200416-910961
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT" with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS" resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS" . The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development. https://www.wsj.com/articles/PR-CO-20200416-910961
(0)
(0)Scroll down for more posts ▼